文献速递前列腺癌

恩扎卢胺与阿比特龙治疗转移性去势抵抗性前列腺癌的生活质量:系统评价与荟萃分析

Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-04-05

该系统评价与荟萃分析比较了恩扎卢胺与阿比特龙联合泼尼松(AAP)治疗转移性去势抵抗性前列腺癌(mCRPC)患者报告的健康相关生活质量(HRQoL)。纳入8项研究,其中4项随机对照试验(RCT)进入荟萃分析。结果显示AAP短期HRQoL优于恩扎卢胺,但长期差异不明显且长期研究存在严重偏倚风险。

要点

  • AAP短期(12周)FACT-P评分变化优于恩扎卢胺。
  • ≥75岁男性长期HRQoL在AAP组更优。
  • 长期研究存在严重偏倚风险,需谨慎解读。

核心结论

  • AAP似乎与比恩扎卢胺更好的短期HRQoL相关。
  • 这种差异在较长随访中不明显,但长期研究存在严重偏倚风险。

研究设计与样本

  • 系统评价与荟萃分析,检索截至2020年6月,遵循PRISMA推荐。
  • 纳入8项研究,其中4项RCT符合荟萃分析条件。
  • 患者报告结局(PROs)截至末次随访进行叙述性总结。
  • 短期(12周)HRQoL变化用FACT-P总分比较,并分别对恩扎卢胺和AAP进行荟萃分析。

主要发现

  • 荟萃分析显示恩扎卢胺组12周FACT-P平均组内变化为-1.3分(95%CI -2.7; 0.1)。
  • AAP组12周FACT-P平均组内变化为4.7分(95%CI -0.1; 9.6)。
  • 一项RCT显示AAP短期HRQoL更优(FACT-P差异6.8分,95%CI 1.7; 11.8)。
  • 同一RCT显示≥75岁男性AAP长期HRQoL更优(FACT-P差异7.35分,95%CI 2.59; 12.11)。
  • 三项非随机研究显示长期HRQoL无差异,但均存在严重偏倚风险。

关键数值与推荐

  • FACT-P评分越高表示HRQoL越好。
  • 短期变化定义为12周。
  • RCT中AAP短期HRQoL优势为6.8 FACT-P分(95%CI 1.7; 11.8)。
  • ≥75岁男性AAP长期HRQoL优势为7.35 FACT-P分(95%CI 2.59; 12.11)。

临床怎么用

  • 对于mCRPC患者,选择恩扎卢胺或AAP时可考虑短期HRQoL差异。
  • ≥75岁男性可能从AAP获得长期HRQoL获益。
  • 长期HRQoL比较证据受偏倚风险限制,临床决策需结合个体情况。

局限性

  • 纳入试验中PRO报告不一致。
  • 仅一项研究在已发表方案中定义了HRQoL测量方法。
  • 非随机研究存在严重偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enzalutamide and abiraterone acetate plus prednisone (AAP) have similar efficacy in metastatic castration-resistant prostate cancer (mCRPC), but different mechanisms of action. The aim was to compare patient-reported health-related quality of life (HRQoL) in men treated with enzalutamide vs AAP for mCRPC. METHODS: We systematically reviewed the literature in June 2020 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. Patient-reported outcomes (PROs) until the last follow-up were summarised in a narrative synthesis. Short-term changes (12 weeks) in HRQoL, measured by the Functional Assessment of Cancer Therapy-Prostate total score (FACT-P), were compared between treatment groups and were analysed for enzalutamide and AAP in separate meta-analyses. Higher FACT-P scores indicate better HRQoL. RESULTS: Eight studies were included in the systematic review, four of which were randomised clinical trials (RCTs) eligible for the meta-analyses. The meta-analyses showed mean within-subject FACT-P changes from baseline to week 12 of -1.3 points (95% confidence interval [CI] -2.7; 0.1) for enzalutamide and 4.7 points (95% CI -0.1; 9.6) for AAP. One RCT and three non-randomised studies directly compared enzalutamide with AAP. The RCT showed better short-term HRQoL for AAP (6.8 FACT-P-points, 95% CI 1.7; 11.8) and better long-term HRQoL for AAP in men ≥75 years (7.35 FACT-P-points, 95% CI 2.59; 12.11). The non-randomised studies showed no difference in long-term HRQoL but had all a serious risk of bias. Limitations of the included studies include that the PRO in the included trials were inconsistently reported and that only one study defined the HRQoL measures in their published protocol. CONCLUSIONS: AAP seems to be associated with better short-term HRQoL than enzalutamide. This difference was not apparent at longer follow-up, but the long-term studies had serious risks of bias.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Ternov KK, Nolsøe AB, Bratt O, et al. Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021. PMID: 33820951. doi:10.1038/s41391-021-00359-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。